Bayesian age‐period‐cohort analysis and trend prediction of epilepsy disease burden in China, 1990–2021
Epileptic Disorders · 2026-08 · 28 (4) · 1188-1203
DOI: 10.1002/epd2.70264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epileptic Disorders, online erschienen am 11.05.2026. Verfasst von Chao Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Institute of Neuroscience, Northeas…. Hauptthemen laut MEDLINE: Epilepsy, Cost of Illness, Disability-Adjusted Life Years. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study analyzes the trends, age‐period‐cohort effects, and influencing factors of epilepsy burden in China from 1990 to 2021, and predicts future burden to support prevention strategies.
Methods
Data were sourced from the Global Burden of Disease Study (GBD) 2021 study. Joinpoint regression analyzed trends in incidence, prevalence, mortality, and disability‐adjusted life years (DALYs). The BAPC (Bayesian Age‐Period‐Cohort) model evaluated age, period, and cohort effects, and an ARIMA (Autoregressive Integrated Moving Average) model projected burden to 2036.
Results
In 2021, epilepsy cases reached 3.086 million (a 41.67% increase since 1990), while DALYs fell to 1.375 million person‐years (a 35.60% decrease). Age‐standardized incidence and prevalence increased (average annual percent change [AAPC] = 0.78% and 0.42%, respectively), whereas mortality and DALY rates declined (AAPC = −2.65% and −1.79%). After 2019, incidence and prevalence rose sharply, accompanied by a short‐term increase in DALY rates indicating a risk of rebound. Age‐specific burden shifted from a unimodal (0–25 years) to a bimodal distribution (0–14 and 30–34 years), with the highest burden now among working‐age adults. The DALY rate decreased slowest in youths (20–24 years) and fastest in middle‐aged groups (45–55 years). Projections indicate continued declines in mortality but stable yet fluctuating incidence through 2036.
Conclusion
Despite improved mortality and DALY rates, epilepsy incidence and prevalence have increased, and although the overall DALY rate has declined, a recent uptick since 2019 signals the need for continued vigilance and targeted intervention. The shifting burden toward working‐age populations underscores the need for differentiated prevention strategies focusing on young adults and the elderly, emphasizing early intervention and long‐term management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Institute of Neuroscience, Northeastern University, Shenyang, Liaoning, People's Republic of China.
- Department of Neurosurgery, Chinese People's Liberation Army of General Hospital, Beijing, China.
- Department of Neurology, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
ORCID-Profile: Zhiqiang Cui
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiang, C., Ju, K., You, Y., Zhao, Y., Wang, J., Guo, C., & Cui, Z. (2026). Bayesian age‐period‐cohort analysis and trend prediction of epilepsy disease burden in China, 1990–2021. Epileptic Disorders, 28(4), 1188-1203. https://doi.org/10.1002/epd2.70264
Vancouver
Jiang C, Ju K, You Y, Zhao Y, Wang J, Guo C, et al. Bayesian age‐period‐cohort analysis and trend prediction of epilepsy disease burden in China, 1990–2021. Epileptic Disorders. 2026;28(4):1188-1203. doi:10.1002/epd2.70264
BibTeX
@article{Jiang2026,
author = {Jiang, Chao and Ju, Keke and You, Yiming and Zhao, Yan and Wang, Jian and Guo, Chuang and Cui, Zhiqiang},
title = {Bayesian age‐period‐cohort analysis and trend prediction of epilepsy disease burden in China, 1990–2021},
journal = {Epileptic Disorders},
year = {2026},
volume = {28},
number = {4},
pages = {1188--1203},
doi = {10.1002/epd2.70264}
}
EUVIMED